Logo do repositório
 
Publicação

COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation

2022-09-15Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorKislaya, Irina
dc.contributor.authorMachado, Ausenda
dc.contributor.authorMagalhães, Sarah
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorFranco, Rafael
dc.contributor.authorLeite, Pedro Pinto
dc.contributor.authorDias, Carlos Matias
dc.contributor.authorNunes, Baltazar
dc.contributor.institutionCentro de Investigação em Saúde Pública (CISP/PHRC)
dc.contributor.institutionEscola Nacional de Saúde Pública (ENSP)
dc.contributor.pblEuropean Centre for Disease Prevention and Control
dc.date.accessioned2022-12-13T22:18:26Z
dc.date.available2022-12-13T22:18:26Z
dc.date.issued2022-09-15
dc.descriptionFunding Information: The authors are grateful to Marta Barreto and Verónica Gómez from the Department of Epidemiology of Instituto Nacional de Saúde Doutor Ricardo Jorge and Camila Cruz and João Lima from Shared Services of the Health Ministry for their contributions for this work. Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
dc.description.abstractWe measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75–85) and 82% (95% CI: 77–85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55–70) in≥80 year-olds and 74% (95% CI: 66–80) in 60–79 year-olds against hospitalisation, and 63% (95% CI: 57–69) and 65% (95% CI: 54–74) against death.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent146052
dc.identifier.doi10.2807/1560-7917.ES.2022.27.37.2200697
dc.identifier.issn1025-496X
dc.identifier.otherPURE: 48293905
dc.identifier.otherPURE UUID: 69712c78-816e-4691-bcd0-2d8e19482d02
dc.identifier.otherScopus: 85137882956
dc.identifier.otherPubMed: 36111555
dc.identifier.otherPubMedCentral: PMC9479470
dc.identifier.otherWOS: 000869739500003
dc.identifier.urihttp://hdl.handle.net/10362/146191
dc.identifier.urlhttps://www.scopus.com/pages/publications/85137882956
dc.language.isoeng
dc.peerreviewedyes
dc.subjectEpidemiology
dc.subjectPublic Health, Environmental and Occupational Health
dc.subjectVirology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleCOVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulationen
dc.title.subtitlecohort study based on electronic health records, Portugal, May to July 2022en
dc.typejournal article
degois.publication.issue37
degois.publication.titleEurosurveillance
degois.publication.volume27
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Kislaya_Euro_Surveill_2022_27_37.pdf
Tamanho:
142.63 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (ENSP)